Drug Profile
KVI 020
Alternative Names: KVI-020; WYE-160020Latest Information Update: 17 Dec 2013
Price :
$50
*
At a glance
- Originator Procter & Gamble; Wyeth
- Developer Pfizer; Procter & Gamble
- Class Imidazolidines; Phenyl ethers; Small molecules; Sulfonamides
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Supraventricular arrhythmias
Most Recent Events
- 17 Dec 2013 No development reported - Preclinical for Supraventricular arrhythmias in USA (unspecified route)
- 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
- 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble